Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
An Established Pharmacologic Class (EPC) in the FDA NDC Directory: the class FDA records for a product in its PHARM_CLASSES field.
In the NADAC file of 2026-10-14
18 products in the NADAC file of 2026-10-14 have an NDC that FDA lists in this class, covering 1 nonproprietary name as FDA writes them. 18 of them have a Medicare figure on OpenBill.
Being in one class means FDA describes the drugs’ pharmacology the same way. It does not mean one can replace another; that is a question for your prescriber.
Prices per unit: CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · as of 2026-10-14 · retrieved 2026-10-17. Classes: FDA NDC Directory · ndctext.zip · as of 2026-10-16.
The products, with what pharmacies pay per unit
- MOUNJARO 10 MG/0.5 ML PEN
- MOUNJARO 12.5 MG/0.5 ML PEN
- MOUNJARO 15 MG/0.5 ML PEN
- MOUNJARO 2.5 MG/0.5 ML PEN
- MOUNJARO 5 MG/0.5 ML PEN
- MOUNJARO 7.5 MG/0.5 ML PEN
- ZEPBOUND 10 MG/0.5 ML PEN
- ZEPBOUND 10 MG/DOSE (40 MG/2.4 ML) KWIKPEN
- ZEPBOUND 12.5 MG/0.5 ML PEN
- ZEPBOUND 12.5 MG/DOSE (50 MG/2.4 ML) KWIKPEN
- ZEPBOUND 15 MG/0.5 ML PEN
- ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN
- ZEPBOUND 2.5 MG/0.5 ML PEN
- ZEPBOUND 2.5 MG/DOSE (10 MG/2.4 ML) KWIKPEN
- ZEPBOUND 5 MG/0.5 ML PEN
- ZEPBOUND 5 MG/DOSE (20 MG/2.4 ML) KWIKPEN
- ZEPBOUND 7.5 MG/0.5 ML PEN
- ZEPBOUND 7.5 MG/DOSE (30 MG/2.4 ML) KWIKPEN
How to read these prices
OpenBill holds every page to these five rules, written by the project’s owner and quoted word for word:
- A price is a range to expect, never a quote.
- Medicare's price is not your price. Say so on every screen that shows it.
- State which dataset and which effective date produced every figure.
- If a source is stale or a file is empty, show that rather than a zero.
- Disclaimer footer: not medical advice, no warranty, other people's data can be wrong.